AACOMmunities

Federal Funding Opportunities and Resources

Below is a selected list of timely federal funding opportunities that are relevant to the osteopathic medical education community. AACOM updates this resource frequently.  Please bookmark the page for your reference. For a comprehensive listing of federal funding opportunities, please visit Grants.gov.   

The U.S. Department of Health and Human Services (HHS) has developed a Grant Opportunities and Guidance clearinghouse across all departments where you can find information about all aspects of the grant process during the COVID-19 crisis. For example, the NIH webpage provides  information and guidance about extensions, resubmissions, and funding opportunities related to COVID-19.  Its resources are also presented here, in a daily, updated format.

 

Featured Opportunities

March 8 - 19, 2021

National Institute of Health

Medical Scientist Training Program (T32)

Application Due: May 25, 2021

The goal of the Medical Scientist Training Program (MSTP) is to develop a diverse pool of highly trained clinician-scientist leaders available to meet the Nation’s biomedical research needs. Specifically, it provides support to eligible domestic institutions to develop and implement effective, evidence-informed approaches to integrated dual-degree training leading to the award of both clinical degrees, e.g., M.D., D.O., D.V.M., D.D.S., Pharm.D., and research doctorate degrees (Ph.D.). With the dual qualification of rigorous scientific research and clinical practice, graduates will be equipped with the skills to develop research programs that accelerate the translation of research advances to the understanding, detection, treatment and prevention of human disease, and to lead the advancement of biomedical research.

Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to application due date

Application Due: June 15, 2021

This award is a continuation of an NCI program to enhance the diversity of the pool of the cancer research workforce by recruiting and supporting eligible New Investigators and Early Stage Investigators from diverse backgrounds, including from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences.

The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required)

The NCI Transition Career Development Award (K22 Independent Basic Experimental Studies with Humans Required)

The NCI Transition Career Development Award (K22 - Independent Clinical Trial Not Allowed)

Application Due: June 12, 2021

The award represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.

Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

Application Due: November 8, 2021

This opportunity encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.

HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to application due date

Application Due: June 22, 2021

The goal of this funding opportunity is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research - for Initial Translational Efforts in Non-addictive Analgesic Development. These R34 awards will support the building of a research team to collect initial data and recruit additional collaborators. The application must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease.

HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to application due date

Application Due: June 22, 2021

The goal of this award is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies are also responsive. It is not specific for any one or group of pain conditions.

NIOSH Support for Conferences and Scientific Meetings (U13 Clinical Trial Not Allowed)

Letter of Intent Due: 30 days prior to due date

Application Due: May 25, 2021

The purpose of the NIOSH Support for Conferences and Scientific Meetings (U13) is to support high quality scientific meetings, conferences, and workshops that are relevant to NIOSH’s scientific mission and that promote occupational safety and health, NIOSH program priorities, and public health.

BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to application due date.

Application Due: October 15, 2021

This award seeks to develop informatics tools for analyzing, visualizing, and integrating data related to the BRAIN Initiative or to enhance our understanding of the brain. As part of programs of building the informatics infrastructure for the BRAIN Initiative, the award supports several different, but related activities, including modifying existing analysis and visualization tools to deal with BRAIN Initiative data and integrating different types of BRAIN Initiative datasets. Proposing the development of new tools to deal with BRAIN Initiative data is also permitted.

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

Letter of Intent: 30 days prior to application due date

Application Due: August 10, 2021; AIDS Application Due: September 7, 2021

(BPN-Biologics) provide support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This award supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).

The Autoantigens and Neoantigens Function in the Etiology and Pathophysiology of Type 1 Diabetes (R01 Clinical Trial Optional)

Letter of Intent: Due by May 22, 2021

Application Due: June 22, 2021

The award encourages applications from institutions and organizations proposing original research aimed at the characterization of the function of neoepitopes and neoantigens in type 1 diabetes. This includes the function that post-translational modifications might have in the humoral and cell mediated autoimmune responses and overall, in the etiology and pathophysiology of type 1 diabetes.

Centers for Disease Control and Prevention

Drug-Free Communities (DFC) Support Program

Application Due: May 10, 2021

The purpose of the Drug-Free Communities (DFC) Support Program grants is to fund applicants who have never received DFC funding to carry out the two goals of the DFC program: 1) Establish and strengthen collaboration among communities, public and private non-profit agencies, as well as federal, state, local, and tribal governments to support the efforts of community coalitions working to prevent and reduce substance abuse among youth (individuals 18 years of age and younger) and 2) Reduce substance abuse among youth and, over time, reduce substance abuse among adults by addressing the factors in a community that increase the risk of substance abuse and promoting the factors that minimize the risk of substance abuse.

Department of Defense

DoD Lung Cancer, Idea Development Award

Application Due: July 28, 2021

The FY21 LCRP Idea Development Award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from lung cancer. The New Investigator category is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators.

CDMRP PRMRP Technology/Therapeutic Development Award

Application Due: September 2, 2021

This award mechanism is intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, in at least one of the Congressionally directed FY21 PRMRP Topic Areas. Products in development should be responsive to the healthcare needs of military Service Members, Veterans, and/or beneficiaries. The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.

CDMRP PRMRP Investigator Initiated Research Award

Application Due: September 2, 2021

The PRMRP Investigator-Initiated Research Award is intended to support studies that will make an important contribution toward research and/or patient care for a disease or condition related to at least one of the FY21 PRMRP Topic Areas. The rationale for a research idea may be derived from a laboratory discovery, population-based studies, a clinician’s first-hand knowledge of patients, or anecdotal data.

.CDMRP PRMRP Discovery Award

Application Due: May 13, 2021

The intent of the PRMRP Discovery Award is to support innovative, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications. Studies supported by this award are expected to lay the groundwork for future DOD FY21 Peer Reviewed Medical Discovery Award 5 avenues of scientific investigation and should include a well-formulated, testable hypothesis based on a sound scientific rationale and study design.

 

February 22 - March 5, 2021

Department of Defense

Defense Medical Research and Development Program - En Route Care Award

Pre-application deadline: March 31

Application Due: June 23

This award mechanism is to support development of highly innovative materiel and knowledge products to drive critical combat casualty care capabilities to the Warfighter in highly mobile, austere, and extreme environments where evacuation capabilities may be significantly delayed or unavailable and align with the recently published Committee on En Route Combat Casualty Care top 10 research priorities. It focuses on research to knowledge and materiel to improve the en route care and patient movement from point of injury to definitive care by ground, air, and sea but solutions under this award will not be limited to military use, including for those in rural areas, who face challenges with delayed access to hospital-based care. Extramural organizations, including academic institutions are eligible to apply.

Health Resources and Services Administration

Sickle Cell Disease Newborn Screening Follow-up Program

Application Due: April 29, 2021

The purpose of the Follow-Up Program is to facilitate access to quality sickle cell disease (SCD) care by: 1) conducting outreach and working with individuals and families with SCD from the time a newborn screen identifies a child with possible SCD, through diagnosis, treatment and follow-up; 2) providing education to families and providers; 3) disseminating resources; 4) collaborating with state newborn screening programs; and 5) linking individuals and families to community resources, evidence-based SCD care, and care coordination within the communities where they reside to the fullest extent possible.

Substance Abuse and Mental Health Services Administration

Medication Assisted Treatment - Prescription Drug and Opioid Addiction

Application Due: April 27, 2021

The purpose of this program is to expand/enhance access to medication-assisted treatment (MAT) services for persons with an opioid use disorder (OUD) seeking or receiving MAT. The desired outcomes for this program are: 1) an increase in the number of individuals with OUD receiving MAT; and 2) a decrease in illicit opioid drug use and prescription opioid misuse at six-month follow-up.

Provider's Clinical Support System - Universities

Application Due Date: Tuesday, April 20, 2021

SAMHSA is accepting applications for Provider's Clinical Support System - Universities (PCSS-Universities) grants. The purpose of this program is to expand/enhance access to medication-assisted treatment (MAT) services for persons with an opioid use disorder (OUD) seeking or receiving MAT through ensuring the education and training of students in the medical, physician assistant, and nurse practitioner fields. This program's focus is to ensure students fulfill the training requirements needed to obtain a DATA waiver to prescribe MAT in office-based settings. SAMHSA plans to issue approximately 36 awards of up to $150,000 per year for up to 3 years.

National Institutes of Health

AD/ADRD Clinical Trials Short Course (R25 Independent Clinical Trial Not Allowed)

Application Due: May 25, 2021

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. This opportunity will support creative educational activities with a primary focus to expand and diversify the skilled AD/ADRD clinical trial workforce and encourage applications that develop creative and innovative short courses to train the next generation of AD/ADRD clinical trialists in state-of-the-art clinical research skills.

Advancing technologies to improve delivery of pharmacological, gene editing, and other cargoes for HIV and SUD mechanistic or therapeutic research (R01- Clinical Trial Optional)

Letter of Intent Due: 30 days prior to application deadline

Application Due: October 25, 2021

The purpose of this funding opportunity is to develop technologies to improve the delivery of pharmacological, gene editing, or other cargoes for HIV and SUD mechanistic research.

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)

Application Due: June 15, 2021

The purpose of this opportunity is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH’s experimental therapeutics approach, this award is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions.

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)

Application Due: June 15, 2021

The purpose of this opportunity is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness. Pediatric, adult and geriatric focused interventions are appropriate for this award.

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)

Application Due: June 15, 2021

This opportunity seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This award supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings.

First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required)

Application Due: June 15, 2021

The purpose of this opportunity is to encourage cooperative agreement applications to support early- stage clinical trials of novel mechanism of action investigational drugs or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need.

February 8-19, 2021

Agency for Healthcare Research and Quality

Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 - Clinical Trial Optional)

Application Due: May 25, 2021

This opportunity invites applications that propose research projects that test promising digital healthcare interventions aimed at improving quality of care and healthcare services delivery at the point of care. It will use the Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities.

National Institutes of Health

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)

Application Due: April 12, 2021: AIDS Application Due: May 7, 2021

This opportunity supports high quality scientific conferences that are relevant to the NIH's mission and to the public health. A conference is defined as a symposium, seminar, workshop, or any other organized and formal meeting, whether conducted face-to-face or via the internet, where individuals assemble (or meet virtually) for the primary purpose to exchange technical information and views or explore or clarify a defined subject, problem, or area of knowledge, whether or not a published report results from such meeting. The NIH recognizes the value to members of the research community and all other interested parties in supporting such forums.

NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)

Application Due: June 12, 2021

This opportunity provides support for senior investigators who have the expertise and leadership skills to enhance aging and geriatric research capacity within their academic institution.

Centers for Disease Control and Prevention

Core State Injury Prevention Program (Core SIPP)

Application Due: April 19, 2021

This opportunity supports health department infrastructure, data and partnerships to identify and respond to existing and emerging injury threats with data-driven public health actions. These actions are intended to increase protective factors and reduce risk factors using the best available evidence for injuries and death. Such an approach includes engaging in robust data and surveillance, strengthening strategic collaborations and partnerships, and conducting assessment and evaluation. The overall goal of this approach is to inform public health action for injury prevention.